Gemcitabine-Releasing Intravesical System clinical trials
Also written TAR-200 and JNJ-17000139.
How each study uses Gemcitabine-Releasing Intravesical System is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Janssen Research & Development, LLC (5) · Taris Biomedical LLC (3)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Gemcitabine-Releasing Intravesical System, phase 3 first.
- Dec 2026A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderPhase 3 · Janssen Research & Development, LLC
Studies
Open first, then newest update. How each study uses Gemcitabine-Releasing Intravesical System is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyActive, not recruitingPhase 2Janssen Research & Development, LLCNCT04640623Written as TAR-200How we know
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06211764Written as TAR-200How we know
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04658862Written as TAR-200How we know
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT05714202Written as TAR-200How we know
- A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical CystectomyCompletedPhase 1Janssen Research & Development, LLCNCT03404791Written as TAR-200How we know
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedPhase 1Taris Biomedical LLCNCT03518320Written as Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200How we know
- Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder CancerCompletedPhase 1Taris Biomedical LLCNCT02722538Written as Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200How we know
- Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder CancerCompletedPhase 1Taris Biomedical LLCNCT02720367Written as Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200How we know